NCT02664038

Brief Summary

Alcohol Use Disorders (AUDs) have a significant public health impact and are highly prevalent in Veterans. Alcohol related brain effects on neurocognition (attention, memory and executive function) reduce ability to benefit from current treatments. These cognitive impairments are especially common in the early phase of recovery, persist over years and get worse with age. Recent research suggests that cognitive remediation therapy (CRT) may improve attention, memory and executive function in other disorders, and the investigators just completed pilot study with AUD Veterans found significantly greater improvements for those receiving CRT. The proposed study examines AUD outcomes and neurocognitive improvements when CRT is combined with a standardized alcohol treatment. The investigators hypothesize that CRT will improve neurocognition and AUD outcomes more than standardized alcohol treatment alone. Findings will determine whether CRT augmentation can benefit Veterans with AUDs.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
59

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Aug 2016

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 14, 2016

Completed
12 days until next milestone

First Posted

Study publicly available on registry

January 26, 2016

Completed
7 months until next milestone

Study Start

First participant enrolled

August 22, 2016

Completed
5.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2021

Completed
9 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2022

Completed
2.2 years until next milestone

Results Posted

Study results publicly available

August 27, 2024

Completed
Last Updated

August 27, 2024

Status Verified

August 1, 2024

Enrollment Period

5.1 years

First QC Date

January 14, 2016

Results QC Date

November 9, 2022

Last Update Submit

August 22, 2024

Conditions

Keywords

AUDNeuropsychologyCognitive Remediation

Outcome Measures

Primary Outcomes (1)

  • Days of Heavy Alcohol Use Assessed by Weekly Time Line Follow-back and Breathalyzer

    Heavy alcohol use over 90 days as verified by Time Line Follow-back or breathalyzer findings. Minimum = 0. Maximum = 90. Fewer days is better.

    3 months of active treatment

Secondary Outcomes (3)

  • Days of Heavy Alcohol Use Assessed by Weekly Time Line Follow-back and Breathalyzer

    30 days preceding 6 month follow-up, 3 months after active treatment.

  • Penn Alcohol Craving Scale

    6 month follow-up

  • Neurocognitive Composite Score (Average of T-scores for Measures of Attention, Processing Speed, Memory, Delayed Recall, Executive Function)

    Baseline to 6 months

Study Arms (2)

CRT+IDC

EXPERIMENTAL

Cognitive Remediation Therapy for 13 weeks plus Individual Drug Counseling

Behavioral: Cognitive Remediation Training

Computer Game Play+IDC

ACTIVE COMPARATOR

Computer arcade games for 13 weeks plus Individual Drug Counseling

Behavioral: Cognitive Remediation Training

Interventions

Up to 65 hours of computer based cognitive training of attention, verbal and visual memory, verbal and visual working memory, and executive functions

CRT+IDCComputer Game Play+IDC

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Veterans enrolled in VA AUD treatment as usual and Non-Veteran community members in AUD treatment
  • Have a primary diagnosis of AUD and are within 30 days of detoxification or last use at time of recruitment

You may not qualify if:

  • Other medical illnesses that compromise neurocognition
  • Active use of prescribed opioids or benzodiazepines that may hinder new learning
  • Commitment to complete active phase and attend follow-up
  • No pending incarceration or plans to leave the state

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

VA Connecticut Healthcare System West Haven Campus, West Haven, CT

West Haven, Connecticut, 06516, United States

Location

Limitations and Caveats

Due to the pandemic, recruitment was below the 90 subjects proposed.

Results Point of Contact

Title
Morris Bell, Ph.D., Senior Research Career Scientist
Organization
VA Connecticut Healthcare System

Study Officials

  • Morris D. Bell, PhD

    VA Connecticut Healthcare System West Haven Campus, West Haven, CT

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
FED
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 14, 2016

First Posted

January 26, 2016

Study Start

August 22, 2016

Primary Completion

September 30, 2021

Study Completion

June 30, 2022

Last Updated

August 27, 2024

Results First Posted

August 27, 2024

Record last verified: 2024-08

Data Sharing

IPD Sharing
Will not share

Locations